ADDIN EN.REFLIST Alvarez,
R.
D.,
Partridge,
E.
E.,
& Khazaeli,
M.
B.
(1997).
Gynecol.
Oncol.,
65,
94.
Alvarez,
R.
D.,
Partridge,
E.
E.,
Khazaeli,
M.
B.,
Plott,
G.,
Austin,
M.,
Kilgore,
L.,
.
.
.
Meredith,
R.
F.
(1997).
Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study.
Gynecol Oncol,
65(1),
94-101.
https://doi.org/10.1006/gyno.1996.4577
Banerjee,
S.,
Pillai,
M.
R.
A.,
& Knapp,
F.
F.
(2015).
Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry,
Radiochemistry,
and Practical Applications.
Chemical Reviews,
115(8),
2934-2974.
https://doi.org/10.1021/cr500171e
Bonnema,
S.
J.,
& Hegedüs,
L.
(2012).
Radioiodine Therapy in Benign Thyroid Diseases: Effects,
Side Effects,
and Factors Affecting Therapeutic Outcome.
Endocrine Reviews,
33(6),
920-980.
https://doi.org/10.1210/er.2012-1030
Chakraborty,
S.,
Das,
T.,
Sarma,
H.
D.,
Venkatesh,
M.,
& Banerjee,
S.
(2008).
Comparative studies of 177Lu-EDTMP and 177Lu-DOTMP as potential agents for palliative radiotherapy of bone metastasis.
Appl Radiat Isot,
66(9),
1196-1205.
https://doi.org/10.1016/j.apradiso.2008.02.061
Dash,
A.,
Pillai,
M.
R.
A.,
& Knapp,
F.
F.
(2013).
Curr.
Radiopharm.,
6,
152.
Hofman,
M.
S.,
Violet,
J.,
Hicks,
R.
J.,
Ferdinandus,
J.,
Thang,
S.
P.,
Akhurst,
T.,
.
.
.
Sandhu,
S.
(2018).
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre,
single-arm,
phase 2 study.
The Lancet Oncology,
19(6),
825-833.
https://doi.org/https://doi.org/10.1016/S1470-2045(18)30198-0
Idée,
J.-M.,
Louguet,
S.,
Ballet,
S.,
& Corot,
C.
(2013).
Theranostics and contrast-agents for medical imaging: a pharmaceutical company viewpoint.
Quantitative imaging in medicine and surgery,
3(6),
292-297.
https://doi.org/10.3978/j.issn.2223-4292.2013.12.06
Ilias,
I.,
Divgi,
C.,
& Pacak,
K.
(2011).
Current role of metaiodobenzylguanidine in the diagnosis of pheochromocytoma and medullary thyroid cancer.
Seminars in Nuclear Medicine,
41(5),
364-368.
https://doi.org/10.1053/j.semnuclmed.2011.03.003
Khan,
S.,
Krenning,
E.
P.,
van Essen,
M.,
Kam,
B.
L.,
Teunissen,
J.
J.,
& Kwekkeboom,
D.
J.
(2011).
Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate.
J Nucl Med,
52(9),
1361-1368.
https://doi.org/10.2967/jnumed.111.087932
Kwekkeboom,
D.
J.,
Bakker,
W.
H.,
Kam,
B.
L.,
Teunissen,
J.
J.
M.,
Kooij,
P.
P.
M.,
de Herder,
W.
W.,
.
.
.
Krenning,
E.
P.
(2003).
Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate.
European Journal of Nuclear Medicine and Molecular Imaging,
30(3),
417-422.
https://doi.org/10.1007/s00259-002-1050-8
Kwekkeboom,
D.
J.,
de Herder,
W.
W.,
van Eijck,
C.
H.
J.,
Kam,
B.
L.,
van Essen,
M.,
Teunissen,
J.
J.
M.,
& Krenning,
E.
P.
(2010).
Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors.
Seminars in Nuclear Medicine,
40(2),
78-88.
https://doi.org/https://doi.org/10.1053/j.semnuclmed.2009.10.004
Palekar-Shanbhag,
P.,
Jog,
S.
V.,
Chogale,
M.
M.,
& Gaikwad,
S.
S.
(2013).
Theranostics for cancer therapy.
Curr Drug Deliv,
10(3),
357-362.
Rahbar,
K.,
Afshar-Oromieh,
A.,
Jadvar,
H.,
& Ahmadzadehfar,
H.
(2018).
PSMA Theranostics: Current Status and Future Directions.
Molecular imaging,
17,
1536012118776068-1536012118776068.
https://doi.org/10.1177/1536012118776068
Siegel,
E.
(1999).
The beginnings of radioiodine therapy of metastatic thyroid carcinoma: a memoir of Samuel M.
Seidlin,
M.
D.
(1895-1955) and his celebrated patient.
Cancer Biother Radiopharm,
14(2),
71-79.
https://doi.org/10.1089/cbr.1999.14.71
Strosberg,
J.
(2017).
NETTER-1 Phase III Trial suggests Quality of Life Improvements in Patients with Midgut Neuroendocrine Tumors.
Journal of Nuclear Medicine,
58(supplement 1),
244-244.
Thakral,
P.,
Singla,
S.,
Yadav,
M.
P.,
Vasisht,
A.,
Sharma,
A.,
Gupta,
S.
K.,
.
.
.
Malhotra,
A.
(2014).
An approach for conjugation of (177) Lu- DOTA-SCN- Rituximab (BioSim) & its evaluation for radioimmunotherapy of relapsed & refractory B-cell non Hodgkins lymphoma patients.
The Indian journal of medical research,
139(4),
544-554.
Ullrich,
M.,
Bergmann,
R.,
Peitzsch,
M.,
Zenker,
E.
F.,
Cartellieri,
M.,
Bachmann,
M.,
.
.
.
Ziegler,
C.
G.
(2016).
Multimodal Somatostatin Receptor Theranostics Using [(64)Cu]Cu-/[(177)Lu]Lu-DOTA-(Tyr(3))octreotate and AN-238 in a Mouse Pheochromocytoma Model.
Theranostics,
6(5),
650-665.
https://doi.org/10.7150/thno.14479
Yao,
J.
C.,
Lombard-Bohas,
C.,
Baudin,
E.,
Kvols,
L.
K.,
Rougier,
P.,
Ruszniewski,
P.,
.
.
.
Wiedenmann,
B.
(2010).
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.
J Clin Oncol,
28(1),
69-76.
https://doi.org/10.1200/JCO.2009.24.2669
Yeong,
C.-H.,
Cheng,
M.-h.,
& Ng,
K.-H.
(2014).
Therapeutic radionuclides in nuclear medicine: current and future prospects.
Journal of Zhejiang University.
Science.
B,
15(10),
845-863.
https://doi.org/10.1631/jzus.B1400131